Find the products and resources you are looking for!
Miltenyi Biotec distribution:
GMP-engineered T cells
Chimeric antigen receptor (CAR) T cell therapy is undoubtedly leading a revolution in cancer therapy1,2. The recent successes of CAR T cell therapy in fighting hematologic malignancies have led to a tremendous increase of interest in the immunotherapeutic field³. The great potential of genetically modified T cells now even expands into the area of solid tumors and infectious diseases⁴. Currently, the manufacturing process of CAR T cells consists of various complex procedures, is labor intensive, and represents one of the biggest challenges in this area. The CliniMACS Prodigy TCT process provides a unique all-in-one solution to these challenges. With the CliniMACS Prodigy Platform, it is possible to generate gene-modified T cells in a standardized and automated process5. It is a breakthrough in cell manufacturing, and a leap to the next generation.
The CliniMACS Prodigy Platform enables the entire workflow for the manufacture of CAR T cells, from T cell selection and activation, to viral transduction, and cell expansion. All cell processing steps are automated, ensuring a highly reproducible and standardized manufacturing process.
During the T cell transduction process, T cells are first enriched by specific selection and then activated overnight. In the next step T cells are transduced with a lentiviral or gamma-retroviral vector. Subsequently, transduced T cells are expanded to the desired cell number for final cell harvest.
For complete regulatory notices click here.
At the end of the CliniMACS Prodigy TCT Process, the final product is harvested in 100 mL buffer of your choice. CAR T cells are then ready for cryopreservation or direct infusion.